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ABSTRACT 
Objective: To estimate validity and reliability of WTP questionnaire which WTP value can be taken as an indication of the monetary value of health 
gains, which may carry information regarding the appropriate height of the cost-effectiveness threshold. 
Methods: Three hundred respondents, in Yogyakarta province, Indonesia, were interviewed during June 2017. We examine a value of WTP 
associated with the following scenarios: 1) improving moderate condition; 2) extending life during terminal illness, and 3) lifesaving. The interview 
ascertained maximum hypothetical WTP for one QALY using a dichotomous bidding format with an open-ended final question, along with questions 
about the socio-economic factors. Concerning validity, the WTP of the 3 versions of hypothetical scenarios were compared as known-group validity 
and analysis of the sensitivity and specificity was performed. Test-retest reliability and alpha Cronbach were employed to measure internal 
consistency.  
Results: Analysis generally confirmed the validity and reliability of the WTP hypothetical scenarios. In terms of known group validity, there was 
significant difference across two scenarios (treatment v. s lifesaving), but no significant difference between mean WTP for treatment and terminal 
illness was found. Mean WTP for terminal illness (38 Million IDR) and lifesaving scenario (16 Million IDR) was significantly higher than that of 
treatment scenario (14 Million IDR). The WTP instrument showed good convergent validity (r=0.784), when comparing correlation between WTP 
value and utility score. Estimation of scenario’s sensitivity and specificity in deriving expected WTP were 70.33 % and 38.98 %, respectively. The 
positive and negative predictive values were 64 % and 46 %. The test-retest reliability of WTP values indices excellent stability and reliability of the 
instrument with Spearman’s rank correlation coefficient of 0.816 (p<0.001) 
Conclusion: This study demonstrated that the WTP instrument is feasible and relatively reliable for measuring the WTP values in Indonesia. For 
wider application of the instrument, its validity should be investigated further. Meanwhile, adoption of WTP as an empirical evidence of societal 
values is encouraged.  
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As health technology assessment is widely used in informing coverage 
decision-making in many countries, an empirical study examining the 
value of the QALY has recently become an important tool in policy 
decision making. Nowadays, more countries in Asia have recently begun 
to adopt economic evaluation-based reimbursement policy [1-3]. The 
relatively new of universal health coverage in Indonesia [4] has 
highlighted the need to undertake economic evaluations, especially cost-
utility analysis (CUA). Interest in using willingness-to-pay when 
undertaking economic evaluations of health care has increased [5-6]. 
Willingness-to-pay refers to a method of valuing the benefits of health 
services with surveys using hypothetical scenarios [7]. Typically, when 
using willingness-to-pay, the benefits of health care services are 
estimated in monetary terms. Willingness-to-pay attempts to determine 
how much individuals are prepared to pay for defined health gain [8].  
Estimating the WTP as s threshold in CUA is theoritical and 
methodological challenge [9-10]. A value of WTP depends on several 
factors including type of health gain as well as patients 
characteristics. A value of WTP may also be placed higher in some 
types of patients with higher illness severity. Furthermore, a value of 
WTP also varied widely on socioeconomic status, duration of health 
gain, and elicitation method used for interviewing [11-13]. As the 
result, applying WTP as a threshold for decision making tool, 
irrespective to context of health gain may create a potential problem. 
Individuals may have preferences for health intervention 
irrespective to the magnitude of the gain. Moreover, it is difficult for 
people to make these informed choices and that surveys asking 
people to state their preference for A versus B are hypothetical [14]. 
However, there is a clear need for a ceiling threshold, and more 
importantly, the threshold should be introduced on the basis of 
empirical evidence on societal values. Many studies have been made 
to estimate the WTP value as a ceiling threshold [2].  
As with all outcome measures, it is important that reliability and 
validity is proven empirically to ensure that non-random error is 
minimized and that an instrument measures what it purports to [15]. 
One of the key concerns with using WTP is the hypothetical nature of 
such studies and the lack of evidence about whether hypothetical WTP 
would match the actual purchase decision [16]. Judgment of 
hypothetical health states is common to all valuation approaches in the 
health field but to date none of the non-monetary techniques have 
been amenable to a direct examination of validity and reliability.  
The objective of this study was to assess validity and reliability of 
WTP questionnaire which can be taken as an indication of the 
monetary value of health gains, which may carry information 
regarding the appropriate height of the cost-effectiveness threshold. 
MATERIALS AND METHODS 
Questionnaire of WTP 
The questionnaire consisted of three main components, namely 
general information, utility measure, and willingness to pay measure 
with three hypothetical scenario. 
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First, each respondent was assigned to imagine being in 1 
hypothetical health state based on versions of questionnaire. 
Descriptive of each hypothetical health state was also provided. In 
this study, Visual analogue scale (VAS) as well as EQ-5D was 
employed to measure utility associated with the assigned 
hypothetical health state. For VAS, the respondents will be asked to 
look at the 20 cm, 0-100 thermometer scale where 100 is labeled 
“The best health state or perfect health“, and 0 is labeled “the worst 
health state or dead”. Then, they were asked to rate their current 
health state and the corresponding hypothetical health state on the 
scale.  
Hypothetical scenarios 
We developed 3 versions of scenarios namely treatment, terminal 
illness and lifesaving. The details of each version are as follow:  
Version 1: treatment with health state 22333 
Now, please imagine that you are staying in Health State 22333. 
(Point out picture of health state 22333 and read the description). 
After 8 mo, you can fully recover and return to perfect health without 
any treatment. (Point out picture of perfect health and read the 
description). Then, please assume that there is a new treatment that 
can make you immediately and fully recover to perfect health (point 
out the picture of perfect health). However, you have to pay-out-of 
pocket for the whole cost of treatment since it does not covered by any 
health insurance. Would you like to pay for the treatment?  
You are required to pay full amount in one time within 6 mo.  
Please ignore any income losses from this ill health, focus only on your 
quality of life over the coming 8 mo.  
Version 2: terminal illness with health state 33443 
Now, please imagine that you are staying in Health State 33443. 
(Point out picture of health state A and read the description). Without 
any treatment, you will die after 1 mo. Please assume that there is a 
new treatment that can extend your life so you will live in health state 
A5 for 5,5 y and 1 mo and then die. However, you have to pay-out-of 
pocket for the whole cost of treatment since it does not covered by any 
health insurance. Would you like to pay for the treatment?  
You are required to pay full amount in one time within 6 mo.  
Please ignore any income losses from this ill health, focus only on your 
quantity of life over the coming 5,5 y.  
Version 3: Heart failure with health state 55555 
Now, please imagine that you have severe disease (Health state 55555). 
Without any treatment, you will die today. Please assume that there is a 
new treatment that can make you fully recover to perfect health (see 
picture) but you will die afte 5 mo. However, you have to pay-out-of 
pocket for the whole cost of treatment since it does not covered by any 
health insurance. Would you like to pay for the treatment?  
You are required to pay full amount in one time within 6 mo.  
Please ignore any income losses from this ill health, focus only on your 
quantity and quality of life over the coming 6 mo. 
WTP elicitation  
Dichotomous bidding technique followed by open-ended questions 
was employed to examine respondents’ WTP for each scenario. For 
treatment scenario, a specified period of time being in that 
hypothetical health state followed by complete recovery was 
assumed. Then, respondents were asked to indicate WTP value for 
the treatment that can make immediately recover to perfect health 
(EQ-5D state: 11111). For terminal illness, 1 mo lead time was 
introduced. In this situation, it was assumed that respondents in 
terminal illness (as described as EQ-5D state 33443) would die after 
one month from today. Respondents were then asked to indicate 
his/her WTP for a specific treatment that could have extended 
his/her life for a certain period. Regarding the lifesaving situation, it 
was assumed that respondents had a serious disease and he/she 
would die immediately. Then, those respondents were asked to pay 
for a treatment that can bring him/her back to full health (EQ5D 
state: 11111) but for only certain period of time.  
To avoid starting point bias, each respondent was randomly 
assigned on a certain starting price. The yes/no answer to the first 
price offered to the respondent determine the next price offered. 
Dichotomous bidding as percentage of GDP per capita was used. If 
the answer is “yes”, the bid amount increased in the second bid. If 
the initial answer was “no”, the bid amount would be reduced. The 
open-ended question was asked after the second bidding to examine 
the maximum WTP amount. If the respondent indicated that he/she 
did not want to pay at all for the treatment, his/her reason(s) for not 
paying is asked. Each respondent was asked to determine his/her 
WTP for the treatment, for which he/she has to pay out-of-pocket 
one time within the next 6 mo. The respondent was asked to 
consider carefully before making his/her decision regarding the 
amount of money he/she is WTP for and the feasibility that he/she 
can pay that amount of money (table 1) 
 
Table 1: Algoritm of dichotomous bidding 
Starting point Time of GDP per capita First bidding value Answer Time of GDP per capita First bidding value 
1 0.02 900,000 No 0.0125 562,500 
   Yes  0,05 2,250,000 
2 0.05 2,250,000 No 0.025 1,125,000 
   Yes  0.01 4,500,000 
3 0.1 4,500,000 No 0.05 2,250,000 
   Yes  0.2 9,000,000 
4 0.2 9,000,000 No 0.1 4,500,000 
   Yes  0.4 18,000,000 
5 0.4 18,000,000 No 0.2 9,000,000 
   Yes  0.8 36,000,000 
6 0.8 36,000,000 No 0.4 18,000,000 
   Yes  1.2 54,000,000 
7 1.2 54,000,000 No 0.8 36,000,000 
   Yes  1.5 67,500,000 
 
Data collection 
Before data collection begins, the proposal was submitted to Ethical 
Review Committee for Research on Human Subjects for approval. 
Data were collected via face-to face interview. Pilot testing was 
performed to ensure appropriateness, and clarity of developed 
questionnaire and scenario. All interviewers were trained and 
interviewer guideline was developed in order to ensure the 
consistency of data collection. During the field work, supervision 
plan was implemented.  
Data analysis 
Descriptive statistics were used to explain demographic and patients 
characteristics as well as the WTP values, using percentage and 
frequencies for the categorical variables and means, SD for the 
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continuous variables. The chi-square test was employed for 
categorical variables and Kruskal-Wallis test was used to evaluate 
the differences between versions of scenario.  
Internal consistency was assessed using Cronbach’s alpha, and 
Spearman’s rank correlation was used to assess test-retest reliability. 
Convergent validity was assessed using Spearman rank correlation 
between WTP values and the scores on utility. Known group validity 
was assessed through the association of three levels of scenario and 
WTP values using Chi square tests. Known group validity was assessed 
by using Kruskal Wallis test, assuming that low level of severity case 
also report lower WTP value. All analysis was performed using SPSS 
version 15.0. The significance level was set at p less than 0.05. 
RESULTS AND DISCUSSION 
Characteristics of respondents 
Sociodemographic information of 300 respondents (response 
rate 75%) classified by each version was displayed in table 2. It 
was found that 30.33% of the respondents were male. Average 
age of the respondents was 40.64 y old with the standard 
deviation of 11.37 y. Most of the respondents (71.33%) 
graduated with primary school education or lower. 
Approximately 75% of the respondents had monthly household 
income lower than 2 million IDR. No significant differences 
across questionnaire versions were found. 
  
Table 2: Sociodemographic characteristics of respondents 





Gender     0.501 
Male 91 (30.33) 33 35 23  
Female 29 (69.64) 67  65 77  
Age 40.64 (11.37) 40 (11.17) 39.88 (11.45) 42.04 (12.41)  
Years (Mean, SD)  40.64 (11.37) 40 (11.17) 39.88 (11.45) 42.04 (12.41) 0.437 
Education      
Primary school or lower 214 (71.33) 74 75 65 0.086 
Secondary school or higher 84 (28.67) 26 25 35  
Number of dependents (Mean, SD) 3.43 (2.34) 3.6 (2.00) 3.5 (2.19) 3.2 (2.56) 0.576 
Income (000 IDR)     0.060 
2,000 IDR or lower 225 (75) 62 84 79  
Higher than 2,000 IDR 75 (25) 38 16 21  
 
Proportions of respondents who were unwilling to pay in each version 
were displayed table 3. It was also found that there were significant 
differences across situations. As shown in table 3, only 3% of the 
respondents indicated that they were unwilling to pay for treatment 
situation while about 9 %, and 29% indicated that they were unwilling to 
pay for life extension during terminal illness, and lifesaving, respectively. 
  
Table 3: Percentage of unwilling to pay for each version 
Hypothetical scenario N (%) p-value 
Treatment (100) 3 (3) <0.001* 
Terminal illness (100) 19 (9)  
Lifesaving (100) 29 (29)  
Total (300) 51 (17)  
*significant at p<0.05 
 
Table 4 shows the reasons for unwillingness to pay for each situation. 
Concerning treatment scenario (version 1), it was found that the most 
frequent reasons for unwilling to pay for treatment was that the given 
health state was not too bad so they could live with it. On the other 
hands, the most frequent reason for unwilling to pay for terminal 
illness was that they do value the treatment but they could not afford 
to pay. Regarding lifesaving situation, “I would rather die right away” 
was the most frequent reasons for unwilling to pay.  
 
Table 4: Reasons for unwilling to pay for three hypothetical scenario 
Reasons for unwilling to pay N (%) p-value 
The given health state is not too bad. 
I could live with it 
4 (7.8) <0.001* 
I would get better anyway, so it is not worth paying for the treatment 7 (13.7)  
I do value the treatment but I cannot  
afford to pay anything for it 
15 (29.4) <0.001** 
I’d rather die right away 25 (49.01)  
Total  51 (100)  
 
Validity and reliability  
Known group validity 
As shown in table 5, among those indicated that they were willing to 
pay, the respondents would pay IDR 24 million more for lifesaving 
as compared to those for treatment.  
In addition, amount of willingness to pay for terminal illness was 
IDR 2 million higher than those for treatment.  
When comparing treatment scenario with terminal illness and 
lifesaving scenario, it was found that there were significant differences 
across these 2 scenarios. Based on our analysis, mean WTP for 
terminal illness and lifesaving scenario was significantly higher than 
that of treatment scenario. However, no significant difference between 
mean WTP for treatment and terminal illness was found. When 
looking at treatment scenario, it was found that mean WTP values for 
treatment (version 1) were significantly lower than those for terminal 
illnesses (version 2) and lifesaving (version 3) condition. 
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Table 5: Known group validity of WTP values across three scenarios 
Hypothetical scenario Mean of WTP Minimum (IDR) Maximum (IDR) P value 
Treatment 14,097,000 1,000,000 100,000,000 0.065** 
Terminal illness 16.715.000 500,000 100,000,000  
Lifesaving  38.890.000 1,000,000 200,000,000 <0.001* 
 
Convergent validity 
Table 6 showed the correlation between WTP value and utility score 
(r=0.784). Respondents were consistent to pay more for the lower 
utility score status. It means that utility score, and context of health 
gains are significant predictors of whether the respondents would 
pay higher or lower. 
  
Table 6: Convergent validity of WTP value and utility score 
WTP value Mean VAS score r 
14,097,000 40.72 1 0.784 
16.715.000 38.70 2  
38.890.000 19.6 3  
Note: 1scenario for treatment, 2scenario for terminal illness, 3
 
Sensitivity and specificity 
To determine how good the hypothetical scenario perform to 
identify responses among respondents willing to pay in three 
situations, sensitivity and specificity were evaluated. For the 
sensitivity and specificity analysis, only two groups of scenarios 
were used, treatment and terminal illness together as one group, and 
lifesaving as the second group. Estimation of scenario sensitivity and 
specificity were 70.33 % and 38.98 %, respectively. The positive and 
negative predictive values were 64 % and 46 %.  
scenario for lifesaving 
Reliability 
Regarding the internal consistency reliability, Cronbach’s alpha 
test was 0.721 for the items of WTP questionnaire, which is 
higher than acceptable value 0.7, indicates excellent reliability. 
Item 1 to 5 to total correlation coefficient ranged from 0.428 to 
0.624 (table 7). The test-retest reliability of WTP values indices 
excellent stability and reliability of the instrument with 
Spearman’s rank correlation coefficient of 0.816 (p<0.001) 
(table 8). 
 
Table 7: Reliability test of questions of WTP scenarios 
Question no mean±SD Corrected item-total correlation Cronbach’s alpha if item deleted 
1 0.596±0.491 0.458 0.752 
2 0.880±0.325 0.437 0.734 
3 0.820±0.384 0.595 0.727 
4 0.836±0.371 0.624 0.716 
5 0.940±0.237 0.428 0.728 
 
Table 8: Test retest reliability 
Hypothetical scenario Mean of WTP-1 Mean of WTP-2 r 
Treatment 14,097,000 15,450,000 0.796 
Terminal illness 16.715.000 17,289,000 0.832 
Lifesaving  38.890.000 36,976,000 0.693 
 
The reliability and validity of willingness-to-pay instruments have not 
been adequately addressed in the literature [12, 17-19]. This is a first 
attempt to predict validity and reliability of WTP scenario using 
dichotomous bidding combined with open ended question through the 
application of societal value perspective in Indonesian context. The 
results of this study appeal for taking WTP as a valid methodology. In 
this study significant difference was found between mean willingness-
to-pay values in terminal illness and lifesaving. This suggests that the 
elicited willingness-to-pay is likely to reflect the real value. 
However, we found a little gap of WTP value between treatment and 
terminal illness. In this case we need to pay attention more about 
participants’ response in hypothetical situation, where participants 
might not be able to imagine the related situation [20]. The 
questionnaires used in this study were rather complex, involving 
hypothetical decision-making scenarios. As a result, we were 
concerned about the respondents’ comprehension of the scenarios, 
which would affect the validity of their responses.  
According to our findings, the responses from the utility score and 
the WTP values were consistent with prior expectations [18, 21]. For 
each scenario, the utility associated with the more severe health 
states was lower than that of the less severe health states. Similarly, 
the WTP associated with the more severe health states was higher 
than that of the less severe health states. 
While societal WTP are needed to make decisions making in 
resource allocations, it should be noted that the methods used is 
often seek to measure an individual’s perspective [8].  
Many studies suggested that hypothetical willingness-to-pay 
typically overestimates real willingness-to-pay [16, 22]. Participants 
may exaggerate willingness-to-pay values and in real life do not 
necessarily behave the same way as stated in their responses [23].  
It has been recommended that the mean willingness-to-pay value 
should be deflated by an ad hoc 50 percent to account for potential 
bias [18]. Despite the advantages of the WTP method compared with 
other approach, uncertainties about reliability and validity have thus 
limited its application in health care decision-making [14]. WTP 
study must be designed carefully and accounted for culturally 
specific issues. 
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Several limitations are need attentions to the study. First, the study 
was unable to differentiate the WTP values of treatment and 
terminal illness, despite the apparently gap between them. 
Experiences with health care services had an impact on patient’s 
preferences and the WTP value. Second, only small sample sizes for 
each scenario, covered only one province and response rate is less 
than 90% which limited the statistical power.  
CONCLUSION 
This study demonstrated that the willingness-to-pay instrument is 
feasible and relatively reliable for measuring the WTP values in 
Indonesia. However, further investigations should be undertaken to 
confirm the validity of the approach, especially with respect to 
treatment services which cover wide range of services. Application 
of the method in other cultural or social contexts would require an 
appropriate adaptation, taking into account characteristics of the 
health care system and sociocultural features. Decision-makers 
should be encouraged to apply the willingness-to-pay approach in 
the economic evaluation threshold. 
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